

K961491



Diagnostics

JUL 22 1996

510(k) Summary

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

1. Submitter name, address, contact Boehringer Mannheim Corporation
2400 Bisso Lane
Concord, CA 94524-4117
(510) 674-0667

Contact Person: Betsy Soares-Maddox

Date Prepared: April 4, 1996

2. Device name Proprietary name: Elecsys® TSH Assay

Common name: Electrochemiluminescence assay for the thyroid stimulating hormone.

Classification name: Radioimmunoassay-thyroid stimulating hormone

3. Predicate device We claim substantial equivalence to the Enzymun-Test® TSH (K915195).

Continued on next page



510(k) Summary, Continued

**4.
Device
Description**

Sandwich principle: Total duration of assay: 18 minutes (37°C).

- 1st Incubation (9 minutes): Sample (50µL), a biotinylated monoclonal TSH-specific antibody (60 µL), and a monoclonal TSH-specific antibody labeled with a ruthenium complex (50 µL) react to form a sandwich complex.
 - 2nd Incubation (9 minutes): After addition of streptavidin-coated microparticles (40 µL) the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
 - The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell.
 - Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier (0.4 second read frame).
 - Results are determined via a calibration curve which is instrument-specifically generated by a 2-point calibration curve and a master curve provided via the reagent bar code.
-

**5.
Intended use**

Immunoassay for the in vitro quantitative determination of Thyroid Stimulating Hormone in human serum and plasma.

**6.
Comparison
to predicate
device**

The Boehringer Mannheim Elecsys® TSH is substantially equivalent to other products in commercial distribution intended for similar use. Most notably it is substantially equivalent to the currently marketed Enzygmun-Test® TSH.

The following table compares the Elecsys® TSH with the predicate device, Enzygmun-Test® TSH.

Similarities:

- Intended Use: Immunoassay for the in vitro quantitative determination of Thyroid Stimulating Hormone
 - Sample type: Serum and plasma
 - Antibody: Mouse Monoclonal anti-TSH
 - Solid phase binding principle: Streptavidin/Biotin
 - Assay standardization: World Health Organization (WHO)
-

Continued on next page



510(k) Summary, Continued

6.
Substantial
equivalence,
cont.

Differences:

Feature	Elecsys® TSH	Enzymun-Test® TSH
Reaction test principle	Electrochemiluminescence	ELISA/1-step sandwich assay using streptavidin technology
Instrument required	Elecsys® 2010	ES 300
Assay Range	Reportable Range: 0.01 $\mu\text{U/ml}$ - 100 $\mu\text{U/ml}$	Reportable Range: 0.03 $\mu\text{U/ml}$ - 40.00 $\mu\text{U/ml}$
Calibration Stability	A calibration is recommended every 7 days if kit is not consumed; 4 weeks with same reagent lot if reagent is consumed within 7 days.	Calibration is required every 2 weeks

Performance Characteristics:

Feature	Elecsys® TSH			Enzymun-Test® TSH		
Precision	Modified NCCLS ($\mu\text{U/ml}$):			Modified NCCLS ($\mu\text{U/ml}$):		
Level	<u>Sample</u>	<u>Control 1</u>	<u>Control 2</u>	<u>Low</u>	<u>Mid</u>	<u>High</u>
N	60	60	60	120	120	120
Within-Run	0.914	2.451	10.670	0.09	1.23	23.13
%CV	2.08	1.88	1.47	20.0	2.7	2.6
Total	0.914	2.451	10.670	0.09	1.23	23.13
%CV	3.28	2.20	1.76	48.9	5.2	4.6
Sensitivity	Functional Sensitivity: 0.01 $\mu\text{U/ml}$					
	Lower Detection Limit: 0.005 $\mu\text{U/mL}$			Lower Detection Limit: 0.03 $\mu\text{U/ml}$		

Continued on next page

510(k) Summary, Continued

6.
Substantial
equivalence,
cont.

Performance Characteristics:

Feature	Elecsys® TSH	Enzymun-Test® TSH															
Linearity	0.01 µU/mL - 100 µU/mL (within ±10% deviation from the linear line)	0.03 µU/mL - 40.00 µU/mL (within ±10% deviation from the linear line)															
Method Comparison	Vs Enzymun-Test® TSH <u>Least Squares:</u> $y = 1.09x + 0.14$ $r = 0.991$ $SEE = 0.798$ $N = 132$ <u>Passing/Bablok:</u> $y = 1.12X - 0.05$ $r = 0.991$ $SEE = 0.798$ $N = 132$	Vs Nichols 3rd Generation <u>Least Squares:</u> $y = 1.02x - 0.24$ $r = 0.985$ $SEE = 1.12$ $N = 142$															
Interfering substances	No interference at:	No interference at:															
Bilirubin	25 mg/dL	64.5 mg/dL															
Hemoglobin	1 g/dL	1 g/dL															
Lipemia	1500 mg/dL	1250 mg/dL															
Biotin	30 ng/mL	30 ng/mL															
RF	339 IU/mL	No concentration reported															
Specificity	<table> <tr> <th></th><th>Conc</th><th>% Cross-Reactivity</th></tr> <tr> <td>HCG</td><td>200</td><td>0</td></tr> <tr> <td>LH</td><td>400</td><td>0.038</td></tr> <tr> <td>FSH</td><td>400</td><td>0.008</td></tr> <tr> <td>HGH</td><td>400</td><td>0.00004</td></tr> </table>		Conc	% Cross-Reactivity	HCG	200	0	LH	400	0.038	FSH	400	0.008	HGH	400	0.00004	No Cross-Reactivity detected at: 200 U/mL 200 mU/mL 200 mU/mL Not reported
	Conc	% Cross-Reactivity															
HCG	200	0															
LH	400	0.038															
FSH	400	0.008															
HGH	400	0.00004															